AnaptysBio (NASDAQ:ANAB) Price Target Raised to $100.00 at Guggenheim

AnaptysBio (NASDAQ:ANAB) had its price objective lifted by equities researchers at Guggenheim from $90.00 to $100.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target suggests a potential upside of 188.54% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. UBS Group reaffirmed a “neutral” rating and set a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Barclays assumed coverage on AnaptysBio in a report on Monday, October 13th. They issued an “overweight” rating and a $78.00 target price on the stock. Stifel Nicolaus increased their target price on AnaptysBio from $55.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Wedbush increased their target price on AnaptysBio from $45.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $61.30.

AnaptysBio Trading Down 0.2%

AnaptysBio stock traded down $0.08 during mid-day trading on Wednesday, hitting $34.66. The company had a trading volume of 46,622 shares, compared to its average volume of 698,062. The stock’s 50 day moving average price is $27.75 and its two-hundred day moving average price is $24.37. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $39.78. The company has a market capitalization of $970.40 million, a PE ratio of -7.90 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%.The business had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. Equities research analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the period. AlphaQuest LLC bought a new stake in AnaptysBio during the 3rd quarter valued at approximately $277,000. New York State Common Retirement Fund raised its stake in AnaptysBio by 33.6% during the 3rd quarter. New York State Common Retirement Fund now owns 10,586 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 2,662 shares during the period. Federated Hermes Inc. raised its stake in AnaptysBio by 2,236.6% during the 3rd quarter. Federated Hermes Inc. now owns 193,327 shares of the biotechnology company’s stock valued at $5,920,000 after purchasing an additional 185,053 shares during the period. Finally, Covestor Ltd raised its stake in AnaptysBio by 131,540.0% during the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 6,577 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.